Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC

Video

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® regarding the emergence of cabozantinib (Cabometyx) as a treatment option for patients with renal cell carcinoma and discussed future research around the drug from an abstract on the SWOG 1500 trial (NCT02761057) at the 2021 Genitourinary Cancers Symposium.

Transcription:

From here on out, it’s going to be the infrequent patient that receives sunitinib (Sutent) in the frontline setting, outside of perhaps clinical trials. I think that cabozantinib probably should be the gold standard. The big question that emerges is ‘do we combine cabozantinib with immunotherapy now that we can do that for these patients,’ and I would suggest some pause. I would suggest that perhaps it’s better for us to wait until we have randomized data. To that end, we are moving forward with a clinical trial of cabozantinib plus or minus immunotherapy in patients with papillary kidney cancer within the cooperative groups. Once again, it’s a trial…looking at that combination of agents.

Reference:

Pal SK, Tangen C, Thompson IM, et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. Presented at: 2021 Genitourinary Cancers Symposium. Abstract 270.

Recent Videos
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Related Content